|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
Patients received alteplase up to 9 hours after the onset or on awakening based on automated perfusion imaging. sICH was ascertained using ECASS II (The Second European-Australasian Acute Stroke Study) criteria.
|
31394994 |
2019 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
|
29171359 |
2018 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
Symptoms of acute stroke and MS can overlap and the lack of clear clinical/radiological criteria that alert the patient or clinician to the development of acute stroke in an MS patient compound the dilemma, even leading to the administration of IV alteplase in cases that are later diagnosed as either MS or having an "MS flare."
|
30135678 |
2018 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
In many countries, thrombolysis with intravenous alteplase has become a central part of acute stroke care in recent years, requiring radical restructuring of services.
|
28120326 |
2017 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
In the absence of active bleeding or known malignancy of the central nervous system, intravenous alteplase seems a reasonable option for patients with an active cancer and acute stroke.
|
31288236 |
2019 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the safety and efficacy of tenecteplase versus alteplase in patients with acute stroke who were eligible for intravenous thrombolysis.
|
28780236 |
2017 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
"""Telestroke"" : the application of telemedicine for stroke."
|
9933289 |
1999 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
Tissue plasminogen activator for acute ischemic stroke.
|
7477192 |
1995 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey.
|
17903947 |
2007 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
tPA-associated reperfusion after acute stroke demonstrated by SPECT.
|
9472885 |
1998 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Intravenous thrombolysis for acute ischemic stroke: the phase IV data.
|
17903870 |
2007 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
|
9259745 |
1997 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment.
|
9056608 |
1997 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
|
12221155 |
2002 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
"""Telestroke"" : the application of telemedicine for stroke."
|
9933289 |
1999 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
A method to determine stroke trial success using multidimensional pooled control functions.
|
19286598 |
2009 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator.
|
20536612 |
2010 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
|
9479658 |
1997 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
An open, multicenter trial of recombinant tissue plasminogen activator in acute stroke. A progress report. The rt-PA Acute Stroke Study Group.
|
2124386 |
1990 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
|
12221155 |
2002 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
Code Stroke: rapid transport, triage and treatment using rt-PA therapy. The NINDS rt-PA Stroke Study Group.
|
9479657 |
1997 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.
|
10171637 |
1993 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Biomarker
|
disease |
CTD_human |
Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke.
|
20212195 |
2010 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
An open, multicenter trial of recombinant tissue plasminogen activator in acute stroke. A progress report. The rt-PA Acute Stroke Study Group.
|
2124386 |
1990 |
|
Acute Cerebrovascular Accidents
|
0.360 |
Therapeutic
|
disease |
CTD_human |
In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
|
15087567 |
2004 |